The benefit of using two techniques for sentinel lymph node mapping in breast cancer

Armando Sardi, Ethan Spiegler, Jean Colandrea, David Frishberg, Hardeep Singh, Patricia Regan, Adil Totoonchie, Deepak Merchant, Stephen Hochuli, Viney Setya, John A. Singer

Research output: Contribution to journalArticle

Abstract

Sentinel lymph node (SLN) mapping has revolutionized the way we stage breast cancer. A blue dye technique (BD) and the use of a radiotracer with the assistance of a gamma-detecting probe (GDP) have been used for the identification of the sentinel nodes. Some groups have suggested that only one technique is necessary. The reported false negative rates have been 0 to 12 per cent and success rates as low as 65 per cent. We have prospectively evaluated these techniques and have used both for the identification of the SLN. Ten surgeons participated in this study. From April 1998 through May 1999, 58 patients underwent SLN mapping followed by an axillary lymph node dissection. After the injection of 0.3 to 1.96 mCi of filtered sulfur colloid diluted to 4 mL all patients had preoperative lymphoscintigraphy. Five minutes before surgery 3 to 5 mL of isosulfan blue was injected around the tumor or tumor bed. Even though preoperative lymphoscintigraphy identified an SLN in 35 patients (63%) successful intraoperative detection of an SLN was possible using both techniques in 53 patients (91%). The SLN was detected by the BD and the GDP in 37 (65%) and 45 (80%) respectively. Nineteen patients (33%) were positive for metastatic disease in the axilla. Twenty-two (19%) of 113 SLNs removed were positive for disease. All cases of metastatic disease in the axilla were detected by the mapping technique. False negative rate was 0 per cent. In 11 patients the only positive node was the sentinel node (58%). Furthermore six (32%) patients were upstaged by the use of immunostains for cytokeratin. Twenty-two positive SLNs were detected in the 19 patients. The positive lymph node was identified only by BD in four patients (21%), only by GDP in six patients (31%), and by both techniques in nine patients (47%). We conclude that if only one technique had been used the false negative rate could have been as high as 32 per cent. Both techniques must be used to obtain a low false negative rate and high yield in the identification of the SLN.

Original languageEnglish (US)
Pages (from-to)24-28
Number of pages5
JournalAmerican Surgeon
Volume68
Issue number1
StatePublished - 2002

Fingerprint

Breast Neoplasms
Lymphoscintigraphy
Axilla
Coloring Agents
Sentinel Lymph Node
Colloids
Keratins
Lymph Node Excision
Sulfur
Neoplasms
Lymph Nodes
Injections

ASJC Scopus subject areas

  • Surgery

Cite this

Sardi, A., Spiegler, E., Colandrea, J., Frishberg, D., Singh, H., Regan, P., ... Singer, J. A. (2002). The benefit of using two techniques for sentinel lymph node mapping in breast cancer. American Surgeon, 68(1), 24-28.

The benefit of using two techniques for sentinel lymph node mapping in breast cancer. / Sardi, Armando; Spiegler, Ethan; Colandrea, Jean; Frishberg, David; Singh, Hardeep; Regan, Patricia; Totoonchie, Adil; Merchant, Deepak; Hochuli, Stephen; Setya, Viney; Singer, John A.

In: American Surgeon, Vol. 68, No. 1, 2002, p. 24-28.

Research output: Contribution to journalArticle

Sardi, A, Spiegler, E, Colandrea, J, Frishberg, D, Singh, H, Regan, P, Totoonchie, A, Merchant, D, Hochuli, S, Setya, V & Singer, JA 2002, 'The benefit of using two techniques for sentinel lymph node mapping in breast cancer', American Surgeon, vol. 68, no. 1, pp. 24-28.
Sardi A, Spiegler E, Colandrea J, Frishberg D, Singh H, Regan P et al. The benefit of using two techniques for sentinel lymph node mapping in breast cancer. American Surgeon. 2002;68(1):24-28.
Sardi, Armando ; Spiegler, Ethan ; Colandrea, Jean ; Frishberg, David ; Singh, Hardeep ; Regan, Patricia ; Totoonchie, Adil ; Merchant, Deepak ; Hochuli, Stephen ; Setya, Viney ; Singer, John A. / The benefit of using two techniques for sentinel lymph node mapping in breast cancer. In: American Surgeon. 2002 ; Vol. 68, No. 1. pp. 24-28.
@article{00de0de22a3f4824be3ee7c64b986a9d,
title = "The benefit of using two techniques for sentinel lymph node mapping in breast cancer",
abstract = "Sentinel lymph node (SLN) mapping has revolutionized the way we stage breast cancer. A blue dye technique (BD) and the use of a radiotracer with the assistance of a gamma-detecting probe (GDP) have been used for the identification of the sentinel nodes. Some groups have suggested that only one technique is necessary. The reported false negative rates have been 0 to 12 per cent and success rates as low as 65 per cent. We have prospectively evaluated these techniques and have used both for the identification of the SLN. Ten surgeons participated in this study. From April 1998 through May 1999, 58 patients underwent SLN mapping followed by an axillary lymph node dissection. After the injection of 0.3 to 1.96 mCi of filtered sulfur colloid diluted to 4 mL all patients had preoperative lymphoscintigraphy. Five minutes before surgery 3 to 5 mL of isosulfan blue was injected around the tumor or tumor bed. Even though preoperative lymphoscintigraphy identified an SLN in 35 patients (63{\%}) successful intraoperative detection of an SLN was possible using both techniques in 53 patients (91{\%}). The SLN was detected by the BD and the GDP in 37 (65{\%}) and 45 (80{\%}) respectively. Nineteen patients (33{\%}) were positive for metastatic disease in the axilla. Twenty-two (19{\%}) of 113 SLNs removed were positive for disease. All cases of metastatic disease in the axilla were detected by the mapping technique. False negative rate was 0 per cent. In 11 patients the only positive node was the sentinel node (58{\%}). Furthermore six (32{\%}) patients were upstaged by the use of immunostains for cytokeratin. Twenty-two positive SLNs were detected in the 19 patients. The positive lymph node was identified only by BD in four patients (21{\%}), only by GDP in six patients (31{\%}), and by both techniques in nine patients (47{\%}). We conclude that if only one technique had been used the false negative rate could have been as high as 32 per cent. Both techniques must be used to obtain a low false negative rate and high yield in the identification of the SLN.",
author = "Armando Sardi and Ethan Spiegler and Jean Colandrea and David Frishberg and Hardeep Singh and Patricia Regan and Adil Totoonchie and Deepak Merchant and Stephen Hochuli and Viney Setya and Singer, {John A.}",
year = "2002",
language = "English (US)",
volume = "68",
pages = "24--28",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "1",

}

TY - JOUR

T1 - The benefit of using two techniques for sentinel lymph node mapping in breast cancer

AU - Sardi, Armando

AU - Spiegler, Ethan

AU - Colandrea, Jean

AU - Frishberg, David

AU - Singh, Hardeep

AU - Regan, Patricia

AU - Totoonchie, Adil

AU - Merchant, Deepak

AU - Hochuli, Stephen

AU - Setya, Viney

AU - Singer, John A.

PY - 2002

Y1 - 2002

N2 - Sentinel lymph node (SLN) mapping has revolutionized the way we stage breast cancer. A blue dye technique (BD) and the use of a radiotracer with the assistance of a gamma-detecting probe (GDP) have been used for the identification of the sentinel nodes. Some groups have suggested that only one technique is necessary. The reported false negative rates have been 0 to 12 per cent and success rates as low as 65 per cent. We have prospectively evaluated these techniques and have used both for the identification of the SLN. Ten surgeons participated in this study. From April 1998 through May 1999, 58 patients underwent SLN mapping followed by an axillary lymph node dissection. After the injection of 0.3 to 1.96 mCi of filtered sulfur colloid diluted to 4 mL all patients had preoperative lymphoscintigraphy. Five minutes before surgery 3 to 5 mL of isosulfan blue was injected around the tumor or tumor bed. Even though preoperative lymphoscintigraphy identified an SLN in 35 patients (63%) successful intraoperative detection of an SLN was possible using both techniques in 53 patients (91%). The SLN was detected by the BD and the GDP in 37 (65%) and 45 (80%) respectively. Nineteen patients (33%) were positive for metastatic disease in the axilla. Twenty-two (19%) of 113 SLNs removed were positive for disease. All cases of metastatic disease in the axilla were detected by the mapping technique. False negative rate was 0 per cent. In 11 patients the only positive node was the sentinel node (58%). Furthermore six (32%) patients were upstaged by the use of immunostains for cytokeratin. Twenty-two positive SLNs were detected in the 19 patients. The positive lymph node was identified only by BD in four patients (21%), only by GDP in six patients (31%), and by both techniques in nine patients (47%). We conclude that if only one technique had been used the false negative rate could have been as high as 32 per cent. Both techniques must be used to obtain a low false negative rate and high yield in the identification of the SLN.

AB - Sentinel lymph node (SLN) mapping has revolutionized the way we stage breast cancer. A blue dye technique (BD) and the use of a radiotracer with the assistance of a gamma-detecting probe (GDP) have been used for the identification of the sentinel nodes. Some groups have suggested that only one technique is necessary. The reported false negative rates have been 0 to 12 per cent and success rates as low as 65 per cent. We have prospectively evaluated these techniques and have used both for the identification of the SLN. Ten surgeons participated in this study. From April 1998 through May 1999, 58 patients underwent SLN mapping followed by an axillary lymph node dissection. After the injection of 0.3 to 1.96 mCi of filtered sulfur colloid diluted to 4 mL all patients had preoperative lymphoscintigraphy. Five minutes before surgery 3 to 5 mL of isosulfan blue was injected around the tumor or tumor bed. Even though preoperative lymphoscintigraphy identified an SLN in 35 patients (63%) successful intraoperative detection of an SLN was possible using both techniques in 53 patients (91%). The SLN was detected by the BD and the GDP in 37 (65%) and 45 (80%) respectively. Nineteen patients (33%) were positive for metastatic disease in the axilla. Twenty-two (19%) of 113 SLNs removed were positive for disease. All cases of metastatic disease in the axilla were detected by the mapping technique. False negative rate was 0 per cent. In 11 patients the only positive node was the sentinel node (58%). Furthermore six (32%) patients were upstaged by the use of immunostains for cytokeratin. Twenty-two positive SLNs were detected in the 19 patients. The positive lymph node was identified only by BD in four patients (21%), only by GDP in six patients (31%), and by both techniques in nine patients (47%). We conclude that if only one technique had been used the false negative rate could have been as high as 32 per cent. Both techniques must be used to obtain a low false negative rate and high yield in the identification of the SLN.

UR - http://www.scopus.com/inward/record.url?scp=0036053063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036053063&partnerID=8YFLogxK

M3 - Article

C2 - 12467312

AN - SCOPUS:0036053063

VL - 68

SP - 24

EP - 28

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 1

ER -